Nobel Prize in Medicine Awarded to British-American Trio for Cell/Oxygen Research

Nobel Prize in Medicine Awarded to British-American Trio for Cell/Oxygen Research


William G. Kaelin, MD, of Harvard University, Boston, Massachusetts, Gregg L. Semenza, MD, PhD, of Johns Hopkins University in Baltimore, Maryland, and Sir Peter J. Ratcliffe, FMedSci, of Oxford University in the United Kingdom have been awarded the 2019 Nobel Prize in Physiology or Medicine for their discoveries on how cells sense oxygen and adapt to it.

The Nobel Assembly at the Karolinska Institute in Stockholm, Sweden, made the announcement this morning at a press conference in Stockholm.

(l-r) Drs Sir Peter J. Ratcliffe, Greg Semenza, and William G. Kaelin


According to the Nobel Committee, the discoveries can inform treatments for fighting anaemia, cancer, and other diseases. The work will help to better understand the production of red blood cells, the generation of new blood vessels, and the fine-tuning of the immune system.

"These fundamental findings have greatly increased our understanding of how the body adapts to change," Randall Johnson, professor at the Karolinska Institute and member of the Nobel Assembly, said, according to the Associated Press (AP). "Applications of these findings are already beginning to affect the way medicine is practiced," he said.

The three scientists will receive an equal share of the cash reward of $918,000.

Betsy Nabel, MD, president of Brigham and Women's Hospital in Boston, who is a cardiovascular scientist, said at a press conference this morning at Dana Farber, "The discoveries made by Bill and his colleagues have fundamentally defined how cells in the body sense oxygen and how the cells then respond to an abundance or an absence of oxygen. This oxygen-sensing mechanism is critical for regulating blood vessel tone and is critical in the development of a heart attack and the treatment of heart attack."

Semenza told the press that he and his colleagues were studying a gene in a rare cell type in the kidney when they realized they were on to something much bigger - they discovered that the gene turns on erythropoietin (EPO), which controls red blood cell production when the cells are deprived of oxygen.


The discovery will lead to treatments for people with chronic kidney disease who become anemic when their kidneys stop making EPO. 

He said at the press conference that chronic kidney disease will likely be the first area in which their discovery will be used, but there are many others. He noted that with cancer, cells divide rapidly, consume a lot of oxygen, and become very hypoxic.

The scientists discovered that when the cells become hypoxic, they turn on genes that allow them to metastasise throughout the body.

"Whereas most of the chemotherapy drugs are designed to kill dividing cells that are well oxygenated, there are no treatments that are approved to treat the hypoxic cells within the cancer. We believe it's these cells that survive the therapy and come back and kill the patient," Semenza said.

With cardiovascular disease, he said, "We hope there may be the possibility for new therapies to increase the perfusion of ischemic tissue in diseases such as coronary heart disease and also limb ischemia, which is a major problem, particularly in diabetics, leading in some cases to limb amputation. There are a number of disorders where we hope to make an impact."

In an Oxford press release, Sir John Bell, Regius Professor of Medicine at the University of Oxford, said, "Sir Peter Ratcliffe has made a major contribution to our understanding of how cells respond to low levels of oxygen. He identified the problem 30 years ago here in Oxford and has tenaciously worked through the fine detail of how this system works. It is an impressive story of how a clinician scientist can combine groundbreaking basic science with caring for patients within the NHS [National Health System]."

Andrew Murray, of the University of Cambridge, said the winners' discovery has key implications for heart and lung diseases as well.

"Low oxygen levels are a feature of some of the most life-threatening diseases," he told the AP. "When cells are short of oxygen, as is the case with heart failure and lung disease, the tissues need to respond to that in order to maintain energy levels."


Tramadol tied to higher mortality rates than NSAIDs in osteoarthritis patients

Tramadol tied to higher mortality rates than NSAIDs in osteoarthritis patients

A new study has shown that patients with osteoarthritis (OA)
who were treated with tramadol had a significantly higher ...

George Floyd protests - The CMA's position

Researchers discover biomarks of ALS in teeth


Nordic Cuddle is delighted to be the first company to accredit a cuddle therapy course with The CMA. In doing so, The CMA has brought onboard a new form of touch-therapy which is growing in popularity around the world.

People with endocrine disorders may see their condition worsen as a result of COVID-19, according to a new review published in the Journal of the Endocrine Society.

Veterans suffering from posttraumatic stress disorder (PTSD) may benefit from one simple, inexpensive treatment involving nitrous oxide, commonly known as laughing gas.

New research from The University of Queensland has found that women who have hot flushes and night sweats after menopause are 70 per cent more likely to have heart attacks, angina and strokes.

The COMPLEMENTARY MEDICAL ASSOCIATION (The CMA) © 2012. No part of this site may be reproduced without the express permission of The Complementary Medical Association. If used without prior consent a charge of US $1,000 per article, or mini section is paid (US $50 per word (minimum) will be charged. This is not meant to reflect a commercial rate for the content, but as a punitive cost and to reimburse The CMA for legal fees and time costs). Use of the contents, without permission will be taken as consent to bill the illegal user in full.